

CLAIMS

What is claimed is:

Claim 1. A method of extending survival and/or delaying disease progression by treating a human tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to a monoclonal antibody or antigen binding fragment thereof which has the identifying characteristics of a monoclonal antibody encoded by a clone deposited with the ATCC as accession number PTA-5643 comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden, whereby disease progression is delayed and/or survival is extended.

Claim 2. The method of claim 1 wherein said antibody is conjugated to a cytotoxic moiety.

Claim 3. The method of claim 2 wherein said cytotoxic moiety is a radioactive isotope.

Claim 4. The method of claim 1 wherein said antibody activates complement.

Claim 5. The method of claim 1 wherein said antibody mediates antibody dependent cellular cytotoxicity.

1 Claim 6. The method of claim 1 wherein said antibody is a murine antibody.
2
3 Claim 7. The method of claim 1 wherein said antibody is a humanized
4 antibody.
5
6 Claim 8. The method of claim 1 wherein said antibody is a chimerized
7 antibody.
8
9 Claim 9. An isolated monoclonal antibody or antigen binding fragments
10 thereof encoded by the clone deposited with the ATCC as PTA-5643.
11
12 Claim 10. The isolated antibody or antigen binding fragments of claim 9,
13 wherein said isolated antibody or antigen binding fragments thereof is humanized.
14
15 Claim 11. The isolated antibody or antigen binding fragments of claim 9
16 conjugated with a member selected from the group consisting of cytotoxic moieties,
17 enzymes, radioactive compounds, and hematogenous cells.
18
19 Claim 12. The isolated antibody or antigen binding fragments of claim 9,
20 wherein said isolated antibody or antigen binding fragments thereof is a chimerized
21 antibody.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Claim 13. The isolated antibody or antigen binding fragments of claim 9,
wherein said isolated antibody or antigen binding fragments thereof is a murine antibody.

Claim 14. The isolated clone deposited with the ATCC as PTA-5643.

Claim 15. The method of claim 1 wherein said tumor is a breast tumor.

Claim 16. The method of claim 1 wherein said tumor is an ovarian tumor.